Related Experiment Video
Updated: Jun 10, 2026
12:08
Improving IV Insulin Administration in a Community Hospital
Published on: June 11, 2012
Hypoglycemia in type 1 diabetes mellitus
1Department of Medicine, Washington University School of Medicine, Campus Box 8127, 660 South Euclid Avenue, St Louis, MO 63110, USA. pcryer@wustl.edu
Endocrinology and Metabolism Clinics of North America
|August 21, 2010
Summary
Iatrogenic hypoglycemia in type 1 diabetes mellitus (T1DM) stems from insulin therapy and impaired counter-regulatory responses, causing significant morbidity. New treatments regulating insulin secretion are needed to prevent hypoglycemia and achieve stable blood glucose levels.
Area of Science:
- Endocrinology
- Metabolic Disorders
- Diabetes Research
Background:
- Iatrogenic hypoglycemia is a serious complication for individuals with type 1 diabetes mellitus (T1DM).
- It arises from therapeutic hyperinsulinemia and impaired counter-regulatory mechanisms, leading to hypoglycemia-associated autonomic failure (HAAF).
- Recurrent hypoglycemia causes significant morbidity, can be fatal, and prevents long-term stable blood glucose control (euglycemia).
Purpose of the Study:
- To identify risk factors contributing to iatrogenic hypoglycemia in T1DM.
- To highlight the limitations imposed by recurrent hypoglycemia on diabetes management.
- To emphasize the need for advanced therapeutic strategies to eliminate hypoglycemia in T1DM.
Main Methods:
- Review of factors leading to relative or absolute insulin excess.
- Assessment of indicators for hypoglycemia-associated autonomic failure (HAAF) in diabetic patients.
- Analysis of current treatment limitations in preventing recurrent hypoglycemia.
Main Results:
- Identified risk factors include excessive insulin dosing and HAAF.
- Hypoglycemia-associated autonomic failure (HAAF) compromises the body's natural defense against low blood sugar.
- Current diabetes management strategies are insufficient to prevent recurrent hypoglycemia and achieve euglycemia.
Conclusions:
- Eliminating iatrogenic hypoglycemia is crucial for improving the quality of life for T1DM patients.
- Future treatments must focus on precise, glucose-regulated insulin delivery or secretion.
- Advanced therapeutic approaches are essential to overcome the challenges of recurrent hypoglycemia in T1DM.
Related Concept Videos
01:26Hypoglycemia
Hypoglycemia is a blood glucose level below 70 mg/dL. It commonly occurs in individuals using insulin or insulin-secreting drugs, but may also arise in non-diabetic conditions. People with type 1 diabetes are at the highest risk because they depend on exogenous insulin. People with type 2 diabetes are also at risk, especially when treated with insulin or medications such as sulfonylureas, which increase insulin release regardless of blood glucose levels. It develops when insulin levels exceed...
01:19Type I Diabetes III: Clinical Manifestations
Type 1 diabetes mellitus typically presents with rapid-onset symptoms due to the body’s inability to utilize glucose in the absence of insulin. Since insulin is required for glucose uptake into cells, its deficiency leads to hyperglycemia and cellular energy deprivation, resulting in characteristic clinical features.Polyuria and PolydipsiaOne of the earliest, most prominent symptoms is polyuria (excessive urination). When blood glucose concentrations rise above the renal threshold, the kidneys...
01:22Diabetes Mellitus: Overview and Type I Subtype
Diabetes mellitus is a chronic metabolic disorder characterized by high blood glucose levels due to inadequate insulin production, insulin resistance, or both. The condition affects millions worldwide and can significantly impact their health and quality of life.
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
01:15Hypoglycemia and Glucagon
Without prolonged fasting, healthy individuals maintain blood glucose levels above 3.5 mM due to a well-adapted neuroendocrine counterregulatory system that effectively prevents acute hypoglycemia, a potentially life-threatening condition. The primary clinical scenarios for hypoglycemia encompass diabetes treatment, inappropriate production of endogenous insulin or insulin-like substances by tumors, and the use of glucose-lowering agents in non-diabetic individuals. Notably, hypoglycemia in the...
01:12Type I Diabetes I: Introduction
Type 1 diabetes mellitus is a chronic metabolic disorder characterized by an absolute deficiency of insulin resulting from the autoimmune destruction of pancreatic β-cells. Although it can occur at any age, it is most commonly diagnosed in childhood, adolescence, or early adulthood. The loss of insulin production impairs cellular glucose uptake, resulting in persistent hyperglycemia and necessitating lifelong insulin therapy.Autoimmune Destruction of β-CellsThe hallmark of type 1 diabetes is an...
01:26Type I Diabetes II: Pathophysiology
Type 1 diabetes mellitus arises from an immune-mediated destruction of pancreatic β-cells, resulting in an absolute deficiency of insulin. This process develops in genetically susceptible individuals when autoimmunity, environmental exposures, and immunologic dysregulation converge to trigger a targeted attack on the insulin-producing cells of the pancreas. The β-cells are located within the islets of Langerhans and are essential for regulating blood glucose by facilitating cellular uptake of...